Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P Hughes, Susan Branford, Deborah L White, John Reynolds, Rachel Koelmeyer, John F Seymour, Kerry Taylor, Chris Arthur, Anthony Schwarer, James Morton, Julian Cooney, Michael F Leahy, Philip Rowlings, John Catalano, Mark Hertzberg, Robin Filshie, Anthony K Mills, Keith Fay, Simon Durrant, Henry Januszewicz Show all
BLOOD | AMER SOC HEMATOLOGY | Published : 2008
We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for suboptimal response. The estimated cumulative incidences of complete cytogenetic response (CCR) by 12 and 24 months were 88% and 90%, and major molecular responses (MMRs) were 47% and 73%. In patients who maintained a daily average of 600 mg of imatinib for the first 6 months (n = 60), MMR rates by 12 and 24 months were 55% and 77% compared with 32% and 53% in patients averaging less than 600 mg (P = .037 and .016, respectively). Dose escalation was indicated for 17 patients before 12 months for failure to achieve, or main..View full abstract
This work was supported in part by grants from Novartis Pharmaceuticals Australia and Amgen Australia. T. P. H. is a National Health and Medical Research Council Practitioner Fellow.